Federico De Marchi

Padova, IT 
Padova, IT 

Overview

Federico De Marchi practices practicing medicine in Padova, Italy.

His clinical expertise encompasses Acute Monoblastic Leukemia (AmoL), Acute Megakaryoblastic Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Padova, 31033, Italy
Other Locations
Udine, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
View 1 Less Clinical Trial

23 Total Publications

The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia.
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia.
Journal: Biomedicines
Published: June 07, 2026

Frequently Asked Questions about Federico De Marchi

Is Federico De Marchi a top-rated expert for Acute Monoblastic Leukemia (AmoL)?

MediFind is an objective health platform that identifies experts based on real-world data. Federico De Marchi is classified as an Experienced expert for Acute Monoblastic Leukemia (AmoL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Federico De Marchi participate in research or clinical trials?

Yes. Federico De Marchi has published 23 articles and abstracts on conditions like Acute Monoblastic Leukemia (AmoL). You can view a list of Federico De Marchi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. De Marchi's expertise for a condition
ConditionClose
        View All 23 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile